AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Olema Pharmaceuticals Inc (NASDAQ:OLMA)
10.51 USD
-0.180 1.684%Sponsored Reports
Loading...
| Previous Close (in USD) | 10.69 |
|---|---|
| Change | -0.180 1.684% |
| 52 W H/L (in USD) | 17.791/5.180 |
| EBITDA (in USD) | -112.133M |
| PE Ratio | -- |
| Volume | 1411405 |
| Diluted Eps TTM | -2.00 |
| Total Assets (in USD) | 276.945M |
|---|---|
| Total Liabilities (in USD) | 23.05M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 68.539M |
| Market Cap (in USD) | 506.760 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Employees: 75
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Sean P. Bohen M.D., Ph.D. | Pres, CEO & Director | 1967 |
| 2. | Mr. Shane William Charles Kovacs M.B.A. | Chief Operating & Financial Officer | 1974 |
| 3. | Dr. Cyrus L. Harmon Ph.D. | Chief Research Officer & Director | 1971 |
| 4. | Mr. Kinney Horn | Chief Bus. Officer | 1974 |
| 5. | Dr. Peter J. Kushner Ph.D. | Co-Founder & Sr. Research Fellow | 1939 |
| 6. | Ms. Courtney Dugan | VP of Investor Relations & Communications | NA |
| 7. | Mr. John B. Moriarty Jr. | Exec. VP, Chief Legal Officer & Corp. Sec. | 1968 |
| 8. | Ms. Julie Dexter | VP & Head of People | NA |
| 9. | Dr. David C. Myles Ph.D. | Chief Discovery & Non-Clinical Devel. Officer | 1963 |
| 10. | Ms. Demiana Faltaos Ph.D., Pharm.D. | VP & Head of Clinical Pharmacology | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -104.787M | -71.096M | -22.121M | -4.316M | -2.197M |
| Minority Interest | - | - | - | - | - |
| Net Income | -102.586M | -70.886M | -22.763M | -4.316M | -2.197M |
| Selling General Administrative | 24.714M | 20.391M | 7.824M | 0.403M | 0.386M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | 0.357M | 0.163M | 0.011M | 0.009M | 0.008M |
| Ebit | -107.345M | -71.491M | -21.528M | -4.323M | -2.075M |
| Ebitda | -106.988M | -71.096M | -21.468M | -4.307M | -2.067M |
| Depreciation And Amortization | 0.357M | 0.395M | 0.06M | 0.016M | 0.008M |
| Operating Income | -106.988M | -71.491M | -21.528M | -4.323M | -2.079M |
| Other Operating Expenses | 106.988M | 71.491M | 21.528M | 4.323M | 2.079M |
| Interest Expense | 0.357M | 0.232M | 0.653M | 0M | 0.028M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 2.228M | 0.442M | 0.06M | 0.007M | 0.004M |
| Net Interest Income | 2.228M | 0.442M | -0.593M | 0.007M | -0.024M |
| Income Tax Expense | -2.201M | -0.21M | 0.642M | -0.007M | -0.09M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 106.988M | 71.491M | 21.528M | 4.323M | 2.079M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 2.201M | 0.395M | -0.593M | 0.007M | -0.094M |
| Net Income From Continuing Ops | -104.787M | -71.096M | -22.121M | -4.316M | -2.197M |
| Net Income Applicable To Common Shares | -104.787M | -71.096M | -23.99M | -4.316M | -2.197M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 276.945M | 215.645M | 295.945M | 342.722M | 0.132M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 4.033M | 4.478M | 0.223M | 0.149M | 0.035M |
| Total Liab | 23.05M | 18.099M | 11.376M | 4.585M | 10.726M |
| Total Stockholder Equity | 253.895M | 197.546M | 284.569M | 338.137M | -10.594M |
| Other Current Liab | 17.935M | 15.16M | 0.378M | 3.866M | 0.443M |
| Common Stock | 0.004M | 0.003M | 0.003M | 0.003M | 0.001M |
| Capital Stock | 0.004M | 0.003M | 0.003M | 0.003M | 0M |
| Retained Earnings | -305.632M | -208.977M | -104.19M | -33.094M | -10.762M |
| Good Will | - | - | - | - | - |
| Other Assets | 0M | 2.771M | 0.54M | 342.38M | 0.003M |
| Cash | 68.539M | 23.702M | 287.25M | 338.549M | 0.068M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 21.621M | 16.549M | 9.019M | 4.585M | 1.378M |
| Current Deferred Revenue | - | - | 7.687M | - | - |
| Net Debt | -66.122M | -21.137M | -283.961M | -338.549M | -0.068M |
| Short Term Debt | 0.988M | 1.015M | 0.931M | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 2.417M | 2.565M | 3.289M | - | - |
| Other Stockholder Equity | 559.176M | 408.333M | 388.905M | 371.228M | 0.168M |
| Property Plant Equipment | - | 1.48M | 4.72M | 0.075M | 0.026M |
| Total Current Assets | 266.513M | 208.899M | 287.25M | 342.137M | 0.103M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 193.268M | 180.719M | 273.438M | - | - |
| Net Receivables | 0.673M | 0.319M | 0.13M | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | -0.319M | - | - | - |
| Accounts Payable | 2.698M | 0.374M | 0.023M | 0.719M | 0.935M |
| Accumulated Other Comprehensive Income | 0.347M | -1.813M | -0.149M | -342.722M | -0.08M |
| Non Currrent Assets Other | 8.141M | 2.771M | 3.975M | 0.51M | 0.003M |
| Non Current Assets Total | 10.432M | 6.746M | 8.695M | 0.585M | 0.029M |
| Capital Lease Obligations | 2.417M | 2.565M | 3.289M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 91.842M | -273.863M | -0.056M | -273.863M | -273.863M |
| Total Cashflows From Investing Activities | 91.479M | -275.438M | -0.056M | -0.056M | -0.056M |
| Total Cash From Financing Activities | 0.476M | 1.391M | 358.403M | 358.403M | 5.254M |
| Net Income | -104.787M | -71.096M | -22.121M | -4.316M | -2.197M |
| Change In Cash | 9.89M | -324.737M | 338.481M | -3.081M | 3.078M |
| Begin Period Cash Flow | 13.812M | 338.549M | 0.068M | 3.149M | 0.071M |
| End Period Cash Flow | 23.702M | 13.812M | 338.549M | 0.068M | 3.149M |
| Total Cash From Operating Activities | -82.065M | -50.69M | -19.866M | -3.081M | -2.176M |
| Depreciation | 0.357M | 0.163M | 0.011M | 0.009M | 0.008M |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | 0.476M | 1.391M | -2.289M | 0M | 0M |
| Other Cashflows From Financing Activities | 0.146M | 0.67M | 140.142M | - | 5.254M |
| Capital Expenditures | 0.363M | 1.575M | 0.056M | 0.056M | 0.056M |
| Change In Working Capital | 3.022M | 2.83M | -1.505M | 1.226M | -0.11M |
| Other Non Cash Items | 0.514M | 1.224M | 0.641M | 5.542M | 0.122M |
| Free Cash Flow | -82.428M | -52.265M | -19.922M | -3.081M | -2.176M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 2 years ago | 2288249 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1446120 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 790476 |
| 4. | Polar Capital Biotech S Inc | 2 years ago | 750000 |
| 5. | iShares Russell 2000 ETF | 2 years ago | 627939 |
| 6. | DFA US Targeted Value I | 2 years ago | 434748 |
| 7. | iShares Biotechnology ETF | 2 years ago | 355015 |
| 8. | Candriam Global Equities Oncology | 2 years ago | 353000 |
| 9. | Belfius Equities Cure C Cap | 2 years ago | 353000 |
| 10. | DFA US Small Cap I | 2 years ago | 303224 |
| 11. | Fidelity Extended Market Index | 2 years ago | 293640 |
| 12. | Fidelity Small Cap Index | 2 years ago | 275560 |
| 13. | Victory Science & Technology | 2 years ago | 261909 |
| 14. | Bridge Builder Small/Mid Cap Growth | 2 years ago | 259869 |
| 15. | DFA US Micro Cap I | 2 years ago | 255760 |
| 16. | iShares Russell 2000 Value ETF | 2 years ago | 253467 |
| 17. | Direxion Daily S&P Biotech Bull 3X ETF | 2 years ago | 230264 |
| 18. | Columbia Small Cap Value I A | 2 years ago | 177840 |
| 19. | Columbia Small Cap Value I | 2 years ago | 176940 |
| 20. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 173172 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bvf Inc | 2 years ago | 9135893 |
| 2. | Paradigm Biocapital Advisors LP | 2 years ago | 7903600 |
| 3. | Logos Global Management LP | 2 years ago | 4383875 |
| 4. | BlackRock Inc | 2 years ago | 3263907 |
| 5. | Deep Track Capital, LP | 2 years ago | 3225419 |
| 6. | Vanguard Group Inc | 2 years ago | 2407688 |
| 7. | Dimensional Fund Advisors, Inc. | 2 years ago | 1936157 |
| 8. | Vivo Capital, LLC | 2 years ago | 1873704 |
| 9. | MPM Oncology Impact Management LP | 2 years ago | 1857136 |
| 10. | HHG PLC | 2 years ago | 1221662 |
| 11. | Geode Capital Management, LLC | 2 years ago | 824833 |
| 12. | Woodline Partners LP | 2 years ago | 750279 |
| 13. | Polar Capital Holdings PLC | 2 years ago | 750000 |
| 14. | BRAIDWELL LP | 2 years ago | 704344 |
| 15. | State Street Corporation | 2 years ago | 673170 |
| 16. | Goldman Sachs Group Inc | 2 years ago | 630956 |
| 17. | Victory Capital Management Inc. | 2 years ago | 610649 |
| 18. | Ally Bridge Group (NY) LLC | 2 years ago | 559035 |
| 19. | Marshall Wace Asset Management Ltd | 2 years ago | 547803 |
| 20. | SILVERARC CAPITAL MANAGEMENT, LLC | 2 years ago | 515317 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...